As of May 31, 2025, Almirall SA (ALM.MC) reports a ROE (Return on Equity) of 0.68%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Almirall SA's ROE (Return on Equity)
Over recent years, Almirall SA's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | 0.68% |
| 2023-12-31 | -2.63% |
| 2022-12-31 | 0.32% |
| 2021-12-31 | -3.18% |
| 2020-12-31 | 5.70% |
This slight downward trend highlights how Almirall SA manages its efficiency in generating profits from shareholders' equity over time.
Comparing Almirall SA's ROE (Return on Equity) to Peers
To better understand Almirall SA's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Almirall SA (ALM.MC) | 0.68% |
| Orion Oyj (ORNBV.HE) | 32.83% |
| Cosmo Pharmaceuticals NV (COPN.SW) | 26.74% |
| Laboratorios Farmaceuticos ROVI SA (ROVI.MC) | 23.93% |
| Vectura Group PLC (VEC.L) | 22.48% |
| Dermapharm Holding SE (DMP.DE) | 18.83% |
Compared to its competitors, Almirall SA's ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.